CRO/Sponsor

Research shows four factors best predict successful patient enrollment in clinical trials.

BRIC governements are working to make it easier to conduct trials in country.

Drug, biological supply, and medical device manufacturers must track all payments of over $10.

Knowledge is power, but power is of no value if you don't exercise it.

A simple but overlooked way to save millions of dollars during new drug development.

Two unique techniques help characterize pharmacodynamic drug effects in healthy subjects.

Collaborative communities may hold the key to transforming a half-century's old R&D paradigm.

The proper storage of research documents remains an essential aspect of the clinical trials process.

Transfer of material between the supply cahins can be time consuming and complicated

With more clinical trials conducted overseas, sponsors are facing new obstacles.

Creating a drug's safety profile through the use of benefit-risk assessments during development.

Medicine is not quantum mechanics where we cannot predict when an event will occur

Conducting clinical research in the East brings a new group of challenges to sponsors

Improvements in image acquisition and read quality: A look at the value of standardization in oncology trials.

Better access to information vastly improves the decision-making process.

Noncompliance with the US Foreign Corrupt Practices Act carries heavy penalties.

The importance of openness and loyalty cannot be overlooked when cultivating a parternship.

The partnership is an example of how CROs and sponsors interact in the ever-evolving clinical trial industry.

Lessons learned from the recruitment of colorectal cander patients into clinical trials.

Greater product value and innovation accomplished with sponsor-service relationships.

Five industry veterans discuss the growth, impact, and evolution of outsourcing.

A MMG strategic initaitve to address disparities in clinical research participation among Hispanic and Latino communities.

Inappropriate calendar pacakaging is a common occurrence leading to confusion and mistakes.

Doing more harm than good will ultimately force human subject protection system reform.

Organizations are seeking growth and competitive advantage through mergers and acquistions.

Why investigative sites are at financial risk and how it may effect sponsors and CROs.

Collecting too many metrics can lead to misappropriation and misinterpretation.

A new reference guide clarifies uncertainty surrounding this sometimes misunderstood document.

A recent survey uncovers key criteria that influence a sponsor's decision when selecting a CRO.

There is increasing recognition of the need to understand product safety in the real world.